Oncology Central

Nivolumab + ipilimumab combo approved as first-line treatment for advanced renal cell carcinoma

The FDA has approved the first immuno-oncology combination therapy for patients with advanced renal cell carcinoma. The Phase III CheckMate-214 clinical trial was conducted by Bristol-Myers Squibb (Uxbridge, UK) and aimed to find an alternative first line treatment for intermediate- and poor-risk advanced renal cell carcinoma (RCC).
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.